GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBHMY) » Definitions » EV-to-FCF

SBHMY (Sino Biopharmaceutical) EV-to-FCF : 12.60 (As of Mar. 26, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Sino Biopharmaceutical EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sino Biopharmaceutical's Enterprise Value is $8,951 Mil. Sino Biopharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was $711 Mil. Therefore, Sino Biopharmaceutical's EV-to-FCF for today is 12.60.

The historical rank and industry rank for Sino Biopharmaceutical's EV-to-FCF or its related term are showing as below:

SBHMY' s EV-to-FCF Range Over the Past 10 Years
Min: 10.52   Med: 26.66   Max: 53.28
Current: 12.74

During the past 13 years, the highest EV-to-FCF of Sino Biopharmaceutical was 53.28. The lowest was 10.52. And the median was 26.66.

SBHMY's EV-to-FCF is ranked worse than
59.91% of 424 companies
in the Biotechnology industry
Industry Median: 3.285 vs SBHMY: 12.74

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-26), Sino Biopharmaceutical's stock price is $8.95. Sino Biopharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.526. Therefore, Sino Biopharmaceutical's PE Ratio (TTM) for today is 17.02.


Sino Biopharmaceutical EV-to-FCF Historical Data

The historical data trend for Sino Biopharmaceutical's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical EV-to-FCF Chart

Sino Biopharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.65 25.28 18.04 14.76 -

Sino Biopharmaceutical Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.04 - 14.76 - -

Competitive Comparison of Sino Biopharmaceutical's EV-to-FCF

For the Biotechnology subindustry, Sino Biopharmaceutical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's EV-to-FCF falls into.



Sino Biopharmaceutical EV-to-FCF Calculation

Sino Biopharmaceutical's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=8951.230/710.575
=12.60

Sino Biopharmaceutical's current Enterprise Value is $8,951 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was $711 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical  (OTCPK:SBHMY) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Sino Biopharmaceutical's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=8.95/0.526
=17.02

Sino Biopharmaceutical's share price for today is $8.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $0.526.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Sino Biopharmaceutical EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

Sino Biopharmaceutical Headlines

From GuruFocus

Sino Biopharmaceutical Ltd's Dividend Analysis

By GuruFocus Research 06-11-2024

Value Idea Contest: Sino Biopharmaceutical

By Matthew Sipos Matthew Sipos 01-10-2019

Matthews China Fund Comments on Sino Biopharmaceutical

By Sydnee Gatewood Sydnee Gatewood 10-25-2019

GuruFocus Value Idea Contest Sees 2 Winners!

By Holly LaFon Holly LaFon 07-12-2019

Matthews China Fund Comments on Sino Biopharmaceutical

By Vera Yuan Vera Yuan 10-20-2014